These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 32646614)

  • 41. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
    Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
    Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma.
    Del Savio E; Maestro R
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Loss of BRG1 (
    Saunders J; Ingley K; Wang XQ; Harvey M; Armstrong L; Ng T; Dunham C; Bush J
    Pediatr Dev Pathol; 2020; 23(2):132-138. PubMed ID: 31403913
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
    Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BAFfling pathologies: Alterations of BAF complexes in cancer.
    Arnaud O; Le Loarer F; Tirode F
    Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Chromatin remodeling defects and cancer: the SWI/SNF example].
    Bourdeaut F; Bièche I
    Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
    Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
    J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subclassification of epithelioid sarcoma with potential therapeutic impact.
    Haefliger S; Chervova O; Davies C; Nottley S; Hargreaves S; Sumathi VP; Amary F; Tirabosco R; Pillay N; Beck S; Flanagan AM; Lyskjaer I
    J Pathol; 2023 Aug; 260(4):368-375. PubMed ID: 37316954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum.
    Chaudet K; Kem M; Lerwill M; Young RH; Mino-Kenudson M; Agaimy A; McCluggage WG; Oliva E
    Histopathology; 2020 Aug; 77(2):231-239. PubMed ID: 32268438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SWI/SNF chromatin remodeling complexes and cancer.
    Biegel JA; Busse TM; Weissman BE
    Am J Med Genet C Semin Med Genet; 2014 Sep; 166C(3):350-66. PubMed ID: 25169151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SWI/SNF-deficient tumors of the central nervous system: An update.
    Hasselblatt M; Kool M; Frühwald MC
    Clin Neuropathol; 2024; 43(1):2-9. PubMed ID: 37969088
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study.
    Chen IY; Ettel MG; Bell PD; Huber AR; Findeis-Hosey JJ; Wang W; Hezel AF; Dunne RF; Drage MG; Agostini-Vulaj D
    Hum Pathol; 2024 Feb; 144():40-45. PubMed ID: 38307342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas.
    Tessier-Cloutier B; Schaeffer DF; Bacani J; Marginean CE; Kalloger S; Köbel M; Lee CH
    Histopathology; 2020 Jul; 77(1):46-54. PubMed ID: 32413172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
    Le Quang M; Ranchère-Vince D; Le Loarer F
    Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SWI/SNF-deficient malignancies of the female genital tract.
    McCluggage WG; Stewart CJR
    Semin Diagn Pathol; 2021 May; 38(3):199-211. PubMed ID: 32978032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
    Nguyen VT; Tessema M; Weissman BE
    Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
    Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
    [No Abstract]   [Full Text] [Related]  

  • 59. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
    Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
    PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.